Recursion PharmaceuticalsRXRX
RXRX
About: Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
Employees: 500
0
Funds holding %
of 7,139 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
141% more first-time investments, than exits
New positions opened: 77 | Existing positions closed: 32
92% more repeat investments, than reductions
Existing positions increased: 113 | Existing positions reduced: 59
67% more funds holding in top 10
Funds holding in top 10: 6 [Q3] → 10 (+4) [Q4]
19% more capital invested
Capital invested by funds: $1.73B [Q3] → $2.06B (+$332M) [Q4]
15% more funds holding
Funds holding: 264 [Q3] → 303 (+39) [Q4]
1% less call options, than puts
Call options by funds: $30.7M | Put options by funds: $30.9M
13.98% less ownership
Funds ownership: 93.36% [Q3] → 79.38% (-13.98%) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$10
8%
upside
Avg. target
$10.50
13%
upside
High target
$11
19%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Needham Gil Blum 22% 1-year accuracy 36 / 167 met price target | 19%upside $11 | Buy Reiterated | 6 Feb 2025 |
Keybanc Scott Schoenhaus 67% 1-year accuracy 24 / 36 met price target | 8%upside $10 | Overweight Maintained | 8 Jan 2025 |
Financial journalist opinion
Based on 15 articles about RXRX published over the past 30 days
Neutral
MarketBeat
23 hours ago
Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA's AI Favorite?
Recursion Pharmaceuticals' NASDAQ: RXRX stock price has seen a dramatic increase, not due to company-specific news or drug announcements, but rather due to actions taken by artificial intelligence (AI) chip giant NVIDIA NASDAQ: NVDA. A recent SEC filing showed NVIDIA reshuffling its AI investment portfolio, and while it trimmed its holdings in several AI ventures, it notably maintained its stake in Recursion Pharmaceuticals.
Neutral
GlobeNewsWire
3 days ago
Altitude Lab Startups Raise $154M in Capital
The Accelerator Awards $150,000 Fellowship to Elnora AI CEO, and Announces Key Cohort Milestones The Accelerator Awards $150,000 Fellowship to Elnora AI CEO, and Announces Key Cohort Milestones
Neutral
Zacks Investment Research
3 days ago
Recursion Pharmaceuticals Before Q4 Earnings: How to Play the Stock
RXRX is expected to provide updates on its oncology and rare disease pipeline in its fourth-quarter earnings release, given the absence of a marketed product.
Positive
The Motley Fool
3 days ago
25 Top AI Stocks That Could Boost Your Portfolio
The artificial intelligence (AI) revolution is reshaping the global economy at an unprecedented pace, with innovations emerging across every sector from healthcare to transportation. As companies race to integrate AI capabilities into products and services, investors are keenly searching for opportunities to capitalize on this technological transformation.
Positive
The Motley Fool
1 week ago
Why Recursion Pharmaceuticals Stock Is Soaring Today
Shares of Recursion Pharmaceuticals (RXRX 16.12%) had soared by 15.8% as of 12:06 p.m. ET on Friday.
Positive
MarketBeat
1 week ago
Biotechs on the Brink: 2 Stocks With Huge Potential
Investors know the biotech industry is a waiting game—smaller companies in this space often work to secure the funding to keep their doors open during a pre-revenue period while they develop drug treatments and other medical products, but the process can be slow and, for those on the outside, opaque. Then, if all goes according to plan, these firms may see success in the form of promising data, successful trial results, or approval from a regulatory agency like the FDA.
Neutral
Zacks Investment Research
1 week ago
Recursion Pharmaceuticals (RXRX) Laps the Stock Market: Here's Why
In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $8.50, indicating a +1.92% shift from the previous trading day.
Positive
Seeking Alpha
1 week ago
Recursion: CDK7 Inhibitor Differentiation Is Initially Paying Off
Company is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. The company is also progressing REC-994 for Cerebral Cavernous Malformation, with phase 2 data expected to be published and FDA guidance sought for further development. The global solid tumor market is expected to reach $375.4 billion by 2034.
Positive
Zacks Investment Research
1 week ago
Recursion Pharmaceuticals (RXRX) Stock Jumps 8.9%: Will It Continue to Soar?
Recursion Pharmaceuticals (RXRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Neutral
Zacks Investment Research
1 week ago
Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider
Recursion Pharmaceuticals (RXRX) closed at $7.66 in the latest trading session, marking a +0.13% move from the prior day.
Charts implemented using Lightweight Charts™